RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …

Combinations of anti-cancer drugs can overcome resistance and provide new treatments,.
The number of possible drug combinations vastly exceeds what could be tested clinically …

Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …

Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF
has enabled a “precision medicine” paradigm to diagnose and treat BRAF-driven tumors …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Acquired or intrinsic resistance to apoptotic and necroptotic stimuli is considered a major
hindrance of therapeutic success in malignant melanoma. Inhibitor of apoptosis proteins …

The three RAS genes comprise the most frequently mutated oncogene family in cancer. With
significant and compelling evidence that continued function of mutant RAS is required for …

Despite immune checkpoint inhibitors (ICIs) have shown the greatest success in melanoma
treatment, only a subset of melanoma patients responds well to ICIs. Thus, identifying …

Background Combination therapy with BRAF and MEK inhibitors significantly improves
survival in BRAF mutated melanoma patients but is unable to prevent disease recurrence …